Glutamate gene polymorphisms predict brain volumes in multiple sclerosis

Multiple Sclerosis Journal

Volumn 19, Issue 3, 2013, Pages 281-288

  Strijbis, Eva M M ^a   Inkster, Becky ^b,c   Vounou, Maria ^b   Naegelin, Yvonne ^d   Kappos, Ludwig ^d   Radue, Ernst Wilhelm ^d   Matthews, Paul M ^c   Uitdehaag, Bernard M J ^a   Barkhof, Frederik ^a   Polman, Chris H ^a   Montana, Giovanni ^b   Geurts, Jeroen J G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

atrophy; endophenotyping; genetics; glutamate; MRI; Multiple sclerosis; single nucleotide polymorphisms; white matter

Indexed keywords

GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A;

ADULT; AGED; ARTICLE; BRAIN SIZE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PHENOTYPIC VARIATION; SINGLE NUCLEOTIDE POLYMORPHISM; WHITE MATTER;

EID: 84874394909     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512454345     Document Type: Article

References (45)

1. Sawcer S, et al. Genetic risk and a primary role for cell-mediate immune mechanisms in multiple sclerosis. Nature. 2011 ; 476: 214-219
2. De Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009 ; 41: 776-782
3. Baranzini SE, Wang J, Gibson RA, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet. 2009 ; 18: 767-778
4. Sawcer S. The complex genetics of multiple sclerosis: Pitfalls and prospects. Brain. 2008 ; 131: 3118-3131
5. Ayers KL, Cordell HJ. SNP selection in genome-wide and candidate gene studies via penalized logistic regression. Genet Epidemiol. 2010 ; 34: 879-891
6. Shi G, Boerwinkle E, Morrison AC, et al. Mining gold dust under the genome wide significance level: A two-stage approach to analysis of GWAS. Genet Epidemiol. 2011 ; 35: 111-118
7. Vounou M, Nichols TE, Montana G. Discovering genetic associations with high-dimensional neuroimaging phenotypes: A sparse reduced-rank regression approach. Neuroimage. 2010 ; 53: 1147-1159
8. Geurts JJ, Wolswijk G, Bo L, et al. Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain. 2003 ; 126: 1755-1766
9. Geurts JJ, Wolswijk G, Bo L, et al. Expression patterns of Group III metabotropic glutamate receptors mGluR4 and mGluR8 in multiple sclerosis lesions. J Neuroimmunol. 2005 ; 158: 182-190
10. Baranzini SE, Srinivasan R, Khankhanian P, et al. Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. Brain. 2010 ; 133: 2603-2611
11. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol. 2005 ; 58: 840-846
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452
13. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage. 2002 ; 17: 479-489
14. Purcell S, Neale B, Todd-Brown K, et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007 ; 81: 559-575
15. Okuda DT, Srinivasan R, Oksenberg JR, et al. Genotype- phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain. 2009 ; 132: 250-259
16. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Royal Statist Soc B. 1995 ; 57: 289-300
17. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Statist. 2001 ; 29: 1165-1188
18. Breiman L. Stacked regressions. Machine Learn. 1996 ; 24: 49-64
19. Breiman L, Friedman J. Predicting multivariate responses in multiple linear regression. J Royal Statist Soc B (Methodological). 1997 ; 59: 3-54
20. Tibshirani R. Regression shrinkage and selection via the Lasso. J Royal Statist Soc B. 1996 ; 58: 267-288
21. Urdinguio RG, Sanchez-Mut JV, Esteller M. Epigenetic mechanisms in neurological diseases: Genes, syndromes, and therapies. Lancet Neurol. 2009 ; 8: 1056-1072
22. Handunnetthi L, Ramagopalan SV, Ebers GC. Multiple sclerosis, vitamin D, and HLA-DRB1*15. Neurology. 2010 ; 74: 1905-1910
23. De Jager PL, Chibnik LB, Cui J, et al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: A weighted genetic risk score. Lancet Neurol. 2009 ; 8: 1111-1119
24. Van Walderveen MA, Lycklama ANG, Ader HJ, et al. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: Relation to clinical characteristics in subgroups of patients with multiple sclerosis. Arch Neurol. 2001 ; 58: 76-81
25. Barkhof F, Bruck W, de Groot CJ, et al. Remyelinated lesions in multiple sclerosis: Magnetic resonance image appearance. Arch Neurol. 2003 ; 60: 1073-1081
26. Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: A longitudinal study. Ann Neurol. 2008 ; 64: 255-265
27. Zivadinov R, Uxa L, Bratina A, et al. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. Int Rev Neurobiol. 2007 ; 79: 521-535
28. Sombekke MH, Lukas C, Crusius JB, et al. HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. Arch Neurol. 2009 ; 66: 1531-1536
29. Baranzini SE, Galwey NW, Wang J, et al. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet. 2009 ; 18: 2078-2090
30. Vounou M, Janousova E, Wolz R, et al. Alzheimer's Disease Neuroimaging Initiative. Sparse reduced-rank regression detects genetic associations with voxel-wise longitudinal phenotypes in Alzheimer's disease. Neuroimage. 2012 ; 60: 700-716
31. Lundström W, Greiner E, Lundmark F, et al. No influence on disease progression of non-HLA susceptibility genes in MS. J Neuroimmunol. 2011 ; 237: 98-100
32. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988 ; 1: 623-634
33. Matute C, Domercq M, Sanchez-Gomez MV.. Glutamate-mediated glial injury: Mechanisms and clinical importance. Glia. 2006 ; 53: 212-224
34. Domercq M, Etxebarria E, Perez-Samartin A, et al. Excitotoxic oligodendrocyte death and axonal damage induced by glutamate transporter inhibition. Glia. 2005 ; 52: 36-46
35. Barkhatova VP, Zavalishin IA, Askarova LS, et al. Changes in neurotransmitters in multiple sclerosis. Neurosci Behav Physiol. 1998 ; 28: 341-344
36. Srinivasan R, Sailasuta N, Hurd R, et al. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain. 2005 ; 128: 1016-1025
37. Vallejo-Illarramendi A, Domercq M, Perez-Cerda F, et al. Increased expression and function of glutamate transporters in multiple sclerosis. Neurobiol Dis. 2006 ; 21: 154-164
38. Pampliega O, Domercq M, Villoslada P, et al. Association of an EAAT2 polymorphism with higher glutamate concentration in relapsing multiple sclerosis. J Neuroimmunol. 2008 ; 195: 194-198
39. Werner P, Pitt D, Raine CS. Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol. 2001 ; 50: 169-180
40. Pina-Crespo JC, Talantova M, Micu I, et al. Excitatory glycine responses of CNS myelin mediated by NR1/NR3 'NMDA' receptor subunits. J Neurosci. 2010 ; 30: 11501-11505
41. Zamponi GW, Stys PK. Role of prions in neuroprotection and neurodegeneration: A mechanism involving glutamate receptors?. Prion. 2009 ; 3: 187-189
42. Micu I, Jiang Q, Coderre E, et al. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature. 2006 ; 439: 988-992
43. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 2009 ; 8: 280-291
44. Salter MG, Fern R. NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature. 2005 ; 438: 1167-1171
45. Salta E, de Strooper B. Non-coding RNAs with essential roles in neurodegenerative disorders. Lancet Neurol. 2012 ; 11: 189-200